Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K. Wenn; L. Tomala; S. Wilop; L. Vankann; C. Hasenbank; O. Frank; A. Hochhaus; F. J. Giles; T. Lange; M. C. Müller; S. Koschmieder; F. Beier; P. Ziegler; T. H. Brümmendorf

doi:10.1038/leu.2015.245

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

K. Wenn^*, L. Tomala, S. Wilop, L. Vankann, C. Hasenbank, O. Frank, A. Hochhaus, F. J. Giles, T. Lange, M. C. Müller, S. Koschmieder, F. Beier, P. Ziegler, T. H. Brümmendorf

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	2402-2404
Number of pages	3
Journal	Leukemia
Volume	29
Issue number	12
DOIs	https://doi.org/10.1038/leu.2015.245
State	Published - Dec 1 2015

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2015.245

Cite this

Wenn, K., Tomala, L., Wilop, S., Vankann, L., Hasenbank, C., Frank, O., Hochhaus, A., Giles, F. J., Lange, T., Müller, M. C., Koschmieder, S., Beier, F., Ziegler, P., & Brümmendorf, T. H. (2015). Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. Leukemia, 29(12), 2402-2404. https://doi.org/10.1038/leu.2015.245

Wenn, K. ; Tomala, L. ; Wilop, S. ; Vankann, L. ; Hasenbank, C. ; Frank, O. ; Hochhaus, A. ; Giles, F. J. ; Lange, T. ; Müller, M. C. ; Koschmieder, S. ; Beier, F. ; Ziegler, P. ; Brümmendorf, T. H. / Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. In: Leukemia. 2015 ; Vol. 29, No. 12. pp. 2402-2404.

@article{fc9cfb3b6d004408bc1ac059b6102eec,

title = "Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib",

author = "K. Wenn and L. Tomala and S. Wilop and L. Vankann and C. Hasenbank and O. Frank and A. Hochhaus and Giles, {F. J.} and T. Lange and M{\"u}ller, {M. C.} and S. Koschmieder and F. Beier and P. Ziegler and Br{\"u}mmendorf, {T. H.}",

note = "Funding Information: honoraria from Novartis, BMS, Pfizer and Ariad and research funding from Novartis. MCM receives honoraria and research funding from Ariad, BMS and Novartis. SK is a consultant and member on an entity{\textquoteright}s Board of Directors or advisory committees for Novartis and receives honoraria and research funding by Novartis. THB is a consultant and receives honoraria from Ariad, BMS, Novartis and Pfizer, he holds patents and royalties at Novartis and receives research funding from Novartis. The remaining authors declare no conflict of interest. Funding Information: SW has an advisory role for Astellas, Merck and Janssen, he receives research funding from Enceladus and travel is sponsored by Merck and Celgene. OF is a Novartis employee. AH receives research funding from Novartis, BMS, Ariad, Pfizer and MSD. FJG is a consultant for Novartis and receives research funding by Novartis. TL receives",

year = "2015",

month = dec,

day = "1",

doi = "10.1038/leu.2015.245",

language = "English (US)",

volume = "29",

pages = "2402--2404",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

Wenn, K, Tomala, L, Wilop, S, Vankann, L, Hasenbank, C, Frank, O, Hochhaus, A, Giles, FJ, Lange, T, Müller, MC, Koschmieder, S, Beier, F, Ziegler, P & Brümmendorf, TH 2015, 'Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib', Leukemia, vol. 29, no. 12, pp. 2402-2404. https://doi.org/10.1038/leu.2015.245

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. / Wenn, K.; Tomala, L.; Wilop, S.; Vankann, L.; Hasenbank, C.; Frank, O.; Hochhaus, A.; Giles, F. J.; Lange, T.; Müller, M. C.; Koschmieder, S.; Beier, F.; Ziegler, P.; Brümmendorf, T. H.

In: Leukemia, Vol. 29, No. 12, 01.12.2015, p. 2402-2404.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

AU - Wenn, K.

AU - Tomala, L.

AU - Wilop, S.

AU - Vankann, L.

AU - Hasenbank, C.

AU - Frank, O.

AU - Hochhaus, A.

AU - Giles, F. J.

AU - Lange, T.

AU - Müller, M. C.

AU - Koschmieder, S.

AU - Beier, F.

AU - Ziegler, P.

AU - Brümmendorf, T. H.

N1 - Funding Information: honoraria from Novartis, BMS, Pfizer and Ariad and research funding from Novartis. MCM receives honoraria and research funding from Ariad, BMS and Novartis. SK is a consultant and member on an entity’s Board of Directors or advisory committees for Novartis and receives honoraria and research funding by Novartis. THB is a consultant and receives honoraria from Ariad, BMS, Novartis and Pfizer, he holds patents and royalties at Novartis and receives research funding from Novartis. The remaining authors declare no conflict of interest. Funding Information: SW has an advisory role for Astellas, Merck and Janssen, he receives research funding from Enceladus and travel is sponsored by Merck and Celgene. OF is a Novartis employee. AH receives research funding from Novartis, BMS, Ariad, Pfizer and MSD. FJG is a consultant for Novartis and receives research funding by Novartis. TL receives

PY - 2015/12/1

Y1 - 2015/12/1

UR - http://www.scopus.com/inward/record.url?scp=84951569512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951569512&partnerID=8YFLogxK

U2 - 10.1038/leu.2015.245

DO - 10.1038/leu.2015.245

M3 - Letter

C2 - 26369986

AN - SCOPUS:84951569512

VL - 29

SP - 2402

EP - 2404

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 12

ER -

Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O et al. Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. Leukemia. 2015 Dec 1;29(12):2402-2404. https://doi.org/10.1038/leu.2015.245

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this